Tetsuya Mitsudomi

Papers

Total Citations

H-Index

About

Tetsuya Mitsudomi is a leading thoracic surgeon and researcher whose work has fundamentally shaped the surgical and molecular management of lung cancer. His research focuses on the intersection of surgical oncology and genomic medicine, particularly the role of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC). Mitsudomi is best known for pioneering studies that established the clinical significance of EGFR mutations as predictive biomarkers for tyrosine kinase inhibitor (TKI) therapy and for defining optimal surgical strategies in molecularly defined patient subgroups. His landmark contributions include demonstrating that EGFR mutation status can guide both neoadjuvant and adjuvant treatment decisions, thereby personalizing surgical care. With over 19,000 citations, his work has been instrumental in translating molecular biology into surgical practice, improving survival outcomes for patients with advanced and early-stage lung cancer. Among his notable achievements, he has served as a key opinion leader in international guidelines for lung cancer surgery and targeted therapy, and his recent evidence-based reviews on surgical practices continue to influence clinical protocols worldwide. Mitsudomi’s career exemplifies how rigorous clinical investigation can bridge the gap between the operating room and the molecular laboratory.